TY - JOUR
T1 - BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
AU - Messina, Carlo
AU - Cattrini, Carlo
AU - Soldato, Davide
AU - Vallome, Giacomo
AU - Caffo, Orazio
AU - Castro, Elena
AU - Olmos, David
AU - Boccardo, Francesco
AU - Zanardi, Elisa
PY - 2020
Y1 - 2020
N2 - Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC patients. Among DDR defects, BRCA mutations show relevant clinical implications. BRCA mutations are associated with adverse clinical features in primary tumors and with poor outcomes in patients with mCRPC. In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. However, concerns still remain on the role of extensive mutational testing in prostate cancer patients, given the implications for patients and for their progeny. The present comprehensive review attempts to provide an overview of BRCA mutations in prostate cancer, focusing on their prognostic and predictive roles.
AB - Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC patients. Among DDR defects, BRCA mutations show relevant clinical implications. BRCA mutations are associated with adverse clinical features in primary tumors and with poor outcomes in patients with mCRPC. In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. However, concerns still remain on the role of extensive mutational testing in prostate cancer patients, given the implications for patients and for their progeny. The present comprehensive review attempts to provide an overview of BRCA mutations in prostate cancer, focusing on their prognostic and predictive roles.
UR - http://www.scopus.com/inward/record.url?scp=85091710281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091710281&partnerID=8YFLogxK
U2 - 10.1155/2020/4986365
DO - 10.1155/2020/4986365
M3 - Review article
AN - SCOPUS:85091710281
VL - 2020
JO - Journal of Oncology
JF - Journal of Oncology
SN - 1687-8450
M1 - 4986365
ER -